A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Recanaclotide (Primary)
  • Indications Non-ulcer dyspepsia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 22 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
    • 20 Oct 2014 According to a Ironwood Pharmaceuticals media release, enrollment in this study was limited by stringent inclusion criteria.
    • 18 Mar 2014 Trial status changed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top